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ABSTRACT 
Objective: To determine the effectiveness of a model osteoarthritis consultation, compared with 
usual care, on physical function and uptake of NICE osteoarthritis recommendations, in adults ≥45 
years consulting with peripheral joint pain in UK general practice. 
Method: Two-arm cluster-randomised controlled trial with baseline health survey. 
Eight general practices in England. Participants: 525 adults ≥45 years consulting for peripheral joint 
pain, amongst 28,443 population survey recipients. Four intervention practices delivered the model 
osteoarthritis consultation to patients consulting with peripheral joint pain; four control practices 
continued usual care. 
The primary clinical outcome of the trial was the SF-12 physical component score (PCS) at six 
months; the main secondary outcome was uptake of NICE core recommendations by six months, 
measured by osteoarthritis quality indicators. A Linear Mixed Model was used to analyse clinical 
outcome data (SF-12 PCS). Differences in quality indicator outcomes were assessed using logistic 
regression. 
Results: 525 eligible participants were enrolled (mean age 67.3 years, SD 10.5; 59.6% female): 288 
from intervention and 237 from control practices. There were no statistically significant differences 
in SF-12 PCS: mean difference at the 6-month primary endpoint was -0.37 (95% CI -2.32, 1.57). 
Uptake of core NICE recommendations by six months was statistically significantly higher in the 
intervention arm compared with control: e.g. increased written exercise information, 20.5% (7.9, 
28.3). 
Conclusion:  Whilst uptake of core NICE recommendations was increased, there was no evidence of 
benefit of this intervention, as delivered in this pragmatic randomised trial, on the primary outcome 
of physical functioning at six months. 
 
Trial registration: ISRCTN06984617 
 
Keywords: osteoarthritis; primary care; implementation; NICE guidelines; self-management; quality 
indicators. 
Running headline: Implementing osteoarthritis guidelines in primary care 
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INTRODUCTION 
Osteoarthritis (OA) is a major cause of pain and disability in older adults: musculoskeletal pain in 
adults aged 45 years and over is the number one cause of years lived with disability worldwide [1]. 
Routine OA management in UK general practice has been found to lack adherence to guidelines 
produced by the National Institute for Health and Care Excellence (NICE) [2], updated in 2014 [3], 
especially for ‘core’ self-management approaches such as written information, exercise and weight 
loss [4-6]. Implementation of the NICE recommendations has not yet been evaluated in UK general 
practice. 
 
Healthcare professionals often frame consultations in terms (such as ‘wear and tear’) thought to 
reassure patients or be patient-friendly which may have a negative impact [7]. Patients and general 
practitioners (GPs) want more advice and support on understanding OA and the use of non-
pharmacological approaches [6,7]. Patient perceived health service needs have also been found to 
align with clinical guideline recommendations [8]. 
 
The MOSAICS (Managing OSteoArthritis In ConsultationS) study was a cluster-randomised controlled 
trial to investigate the effectiveness of a complex intervention - a model OA consultation (MOAC) - 
on clinical outcomes, and on the uptake of core NICE OA core recommendations in participants aged 
≥45 years consulting their GP with peripheral joint pain (hand, hip, knee, foot). 
 
METHODS 
Design 
The MOSAICS study had two key parts: (i) a population health survey that took place between May 
2011 and April 2012, prior to (ii) a two-arm cluster-randomised controlled trial conducted in eight 
general practices in Cheshire, Shropshire or Staffordshire, UK.  The protocol has been published [9] 
and we have previously reported the practice-level evaluation of the intervention using anonymised 
medical records [10]. By using medical record information for measuring the outcomes, all eligible 
patients in the practices were included but no patient reported outcomes were analysed by Jordan 
et al [10]. Here we report the patient-level evaluation of the clinical effectiveness of the Model OA 
Consultation intervention in patients with OA and describe the uptake of core NICE OA 
recommendations for those patients who gave consent to be part of the clinical outcomes study. 
 
Given the practice-level unit of randomisation, it was important to avoid the potential for bias in 
selection and recruitment of participants. We used a population health survey to pre-determine 
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potentially eligible participants prior to consultation for joint pain to establish baseline 
characteristics as the majority of the population are registered with a General Practitioner in 
England. This was mailed to all patients aged ≥45 years eligible to receive a postal survey and 
registered with one of the eight general practices participating in the MOSAICS study. Survey 
participants were asked questions about any joint pain and general health, as well as for permission 
for further contact and medical record review. Those who subsequently consulted their GP for joint 
pain during the trial recruitment phase were invited to take part in the cluster trial. Eligibility of 
potential participants for the cluster trial was identified at this stage and GPs and practice nurses 
therefore played no role in determining eligibility for recruitment to the cluster trial. 
 
The cluster trial was conducted from May 2012 through to February 2014 by the Arthritis Research 
UK Primary Care Centre, Keele University, UK. 
 
Setting and participants 
General practices 
Ten general practices, all using the EMIS electronic health records (EHR) system, were invited to 
participate. Eight practices consented to take part. Eligibility of practices has been described 
elsewhere [9]. Reasons for non-participation included recent engagement with teaching medical 
students and other research involvement. The combined population of patients aged ≥45 years 
registered with the eight participating general practices (estimate 30,000) formed the study 
sampling frame. Resources to support general practice engagement were offered via the UK 
National Institute of Health Research Clinical Research Network [9]. 
 
During a six month run-in period, all practices received a resource pack of written advice with 
examples of patient leaflets about OA provided by Arthritis Research UK and Arthritis Care. An OA 
consultation e-template was designed to collect information on quality indicators of OA care [11]. 
The e-template was installed in all eight practices for the six month baseline period prior to 
randomisation, to make the recording of joint pain consultations part of routine care and determine 
any effect of the e-template on practice. The e-template was triggered in consultations through 
entry of any Read system morbidity code for clinical OA (peripheral joint pain – hand, hip, knee, 
foot); these same Read codes were used to identify patients for the trial. The effects of the e-
template have previously been reported [11]. Briefly, the e-template was associated with increased 
recording of weight measurement and increased prescription of NICE-recommended analgesics 
(topical NSAIDs, paracetamol) in the run-in period, but other care remained stable. 
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Following the six-month run in period, practices were randomised into intervention (four practices) 
or usual care (four practices). All eight practices continued to use the e-template introduced at 
baseline [9,11] to routinely record care in all consultations for joint pain during the study period 
regardless of subsequent recruitment to the trial. 
 
Eligibility criteria for the health survey and the trial are described in Additional File 1, Appendix 1. 
 
Participants 
Eligible registered adults (Additional File 1, Appendix 1) from the eight practices aged ≥45 years were 
mailed a health survey between May 2011 and February 2012. Potential trial participants were 
survey responders reporting peripheral joint pain who provided written consent to further contact 
and medical record review. Those who subsequently consulted their GP for peripheral joint pain 
during the nine month recruitment phase (from April- December 2012) were invited to take part in 
the cluster trial. Fortnightly searches in the medical records identified when the OA template had 
been opened on tagged records which allowed for identification of eligible participants. 
 
Invitations were mailed two weeks after the GP consultation, together with a study information 
sheet and a questionnaire (the ‘post-consultation baseline’) on joint pain, self-management 
approaches, health status and resource use [9]. 
 
Randomisation  
Following the six-month run-in period, general practices were randomly allocated by administrative 
staff at the Keele Clinical Trials Unit (who had no clinical involvement in the trial) to two arms using a 
computer random number generator with block randomisation stratified by practice list size (block 
size, 4): to intervention (MOAC) plus e-template (n=4) or control (usual care) plus e-template (n=4). 
The Principal Investigator and trial administrative members who entered the data were unaware of 
allocation. The trial statisticians were kept blind to the allocation until after the intention-to-treat 
analysis (blinding was broken for per-protocol analysis). 
 
Intervention 
Practices delivered a model OA consultation (MOAC) described in full in Appendix 2, which consisted 
of: an enhanced GP consultation to make, give and explain the diagnosis, and provide initial care for 
older adults presenting with peripheral joint pain; an OA Guidebook offered by the GP to patients to 
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support OA self-management 
(https://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf); advice 
on analgesia; and up to four follow-up practice nurse consultations to guide patients in self-
management for OA with advice on weight management if required, general exercise, and physical 
activity, with goal-setting as appropriate. The development of the intervention has been published 
elsewhere [9,12,13]. Briefly, the intervention followed the Whole Systems Informing Self-
Management Engagement (WISE) model for guided self-management [14] including provision of 
patient information (the OA guidebook) [13], care responsive to patient needs [15], and good access 
to follow-up care (practice nurse consultations). Appendix 2 also provides full details of the training 
for GPs and practice nurses. 
 
Control 
Control practices received no training, guidebook or dedicated nurse OA clinic and continued usual 
care as in the pre-randomisation period. 
 
Patient-level evaluation 
The primary outcome for clinical effectiveness was the SF-12 physical component score (PCS) at six 
months [16]. Uptake of NICE core recommendations during the six months following the index 
consultation was measured by self-reported quality indicators of OA care [17]. Self-management and 
patient enablement were also measured by questionnaires [9,18]. 
 
Secondary outcomes included measures of pain (peripheral joint pain intensity, 
OMERACT/OARSI responder criteria [19]), joint problem self-management (Arthritis Self- 
Efficacy pain subscale), physical activity (IPAQ, Physical Activity Scale for the Elderly [PASE]), and 
Global Assessment of Change [9]. For further details of OMERACT/OARSI responder criteria see 
footnote to Additional File 2, Table 3. Measures of mental health included the SF-12 mental 
component summary (MCS), the eight-item Patient Health Questionnaire depression scale (PHQ8) 
and seven-item Generalised Anxiety Disorder Questionnaire (GAD7) [9]. 
 
Questionnaires were administered by mail after the index consultation (‘post-consultation baseline’) 
and at three, six and 12 months to determine short, medium and longer term outcomes. Non-
responders were invited to complete a minimum data collection. The EQ-5D outcome measure was 
collected to inform the cost-effectiveness analysis, to be reported separately. 
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Treatment fidelity 
To investigate the extent to which participants received the practice nurse component of the MOAC 
intervention, the content, number and percentage of participants in the intervention arm having had 
a practice nurse consultation for OA were identified from case report forms and medical records. 
 
Sample size 
With no prior data on quality indicators of OA in UK primary care, we used the primary clinical 
outcome (SF-12 PCS) for the sample size calculation. In total, 500 participants were needed at 
baseline, allowing for a 20% drop-out, to detect the effect size of 0.3 (‘small to moderate’) with 90% 
power and 5% two-tailed significance at the primary time-point of six months [9]. The sample size 
calculation was adjusted to correct for: clustering (adjusted intracluster correlation coefficient (ICC) 
of 0.005); varying practice size recruitment (including coefficient of variation of 0.5); and repeated-
measures design and dropout (×0.67 and × 1.25 respectively) [9]. 
 
Analysis 
Baseline trial characteristics were compared between treatment arms and presented at the level of: 
(i) trial arms, and (ii) participant characteristics. Longitudinal linear mixed models were used to 
analyse health outcomes: a 3-level hierarchical analysis was carried out accounting for clustering at 
the levels of GP-Practice and individual participants through repeated measures across time 0 
(baseline), 3, 6 and 12 months - including time×group interactions to estimate the treatment effect 
across the three follow up timepoints. Fixed-covariate adjustments were made for age, gender, 
baseline SF-12 PCS, corresponding patient baseline score and practice size (specified a priori within 
the analysis plan). All baseline responders were included in the dataset and the analyses accounted 
for missing data under the ‘missing at random’ (MAR) assumption by modelling the interaction of 
baseline covariates and time – hence retaining the intention-to-treat principle. For dichotomous 
‘quality-indicators’ outcomes, multiple imputation was used to account for missing data (assuming 
MAR) with odds ratio estimates derived from 2-level hierarchical logistic regression models adjusted 
for age, gender and practice size (with GP-Practice as random factor): Absolute percent difference 
estimates were calculated through applying derived odds ratios (intervention versus control 
(reference)) to observed prevalence figures in the control arm. Statistical significance is at the 5% 
(two tailed) level. Analysis was carried using SPSS v.21 (IBM Corp, 2012) and STATA v.13.0/14.0 
(Stata Corp, 2013/5). Sensitivity analyses were conducted for the primary clinical outcome (SF-12 
PCS) (Detailed in Additional File 2, Table 1).  
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RESULTS 
Study recruitment and follow-up 
Mean (SD) practice size for the four intervention practices was 10240.5 (9174.8) and mean number 
of GPs was 6.0 (6.1), compared with 6983.3 (2060.7) and 5.2 (2.9) respectively for the four control 
practices. Trial eligibility, recruitment and follow-up are shown in Figure 1. Of 15,083 eligible 
responders reporting joint pain and consenting to medical record review in the health survey, 651 
participants subsequently consulted for peripheral joint pain during the six month recruitment 
period and were invited to take part in the cluster trial. 525 consented with 288 patients recruited 
from intervention practices and 237 from control practices. 
 
***INSERT FIGURE 1 HERE*** 
 
The median (inter-quartile range) time between the index consultation and response to the post-
consultation baseline questionnaire was 28 (21,40) days for the intervention group, 29 (22,40) for 
the control group. The mean age (SD) was 67.3 years (10.5); 59.6%, were female; 81% had multisite 
pain (pain in two or more of hand, hip, knee, foot). Overall, differences in participant characteristics 
across treatment arms at post-consultation baseline were small (Table 1). Overall follow-up rates 
(including minimum data collection) were: three months, n=470 (89.5%), six months, n=424 (80.8%), 
12 months, n=384 (73.1%). Rates of loss to follow-up were similar for both trial arms (Figure 1). 
 
***INSERT TABLE 1 HERE*** 
 
Clinical effectiveness 
At six months difference between intervention and control arms for the primary clinical outcome 
(Table 2) was not statistically significant (p≥0.05) after adjustment for predefined potential 
confounders. Mean difference in the SF-12 PCS at six months (primary analysis) was -0.37 (95% CI: -
2.32, 1.57) for intervention compared to the control group, which was neither clinically nor 
statistically significant; equating to a standardised mean difference (effect size relative to baseline 
SD of 11.26) of: 0.03 (95% CI: -0.21, 0.14). The crude (unadjusted) intracluster correlation (ICC) was 
small: 0.006 (less than 0.1% when adjusting for baseline).  
 
***INSERT TABLE 2 HERE*** 
 
Uptake of self-management and NICE recommendations 
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Differences between intervention and control arms for the self-reported management offered 
during the six months after the index consultation were statistically significantly greater in the 
intervention arm compared with control for core NICE OA recommendations: information/advice 
about exercises (% difference [95% CI]) 20.5% (7.9%, 28.3%); and paracetamol for pain 10.7 (0.6%, 
20.7%) (Table 3). 
There was a reduction in self-reported use of oral NSAIDs in the intervention arm -15.6% (-28.3%, -
3.5%), and less reliance on walking aids -13.9% (-24.6%, -1.6%), compared with the control arm. 
The statistically non-significant findings for the primary clinical outcome measure (SF-12 
PCS) were largely replicated in the three sensitivity analyses (see Additional File 2, Table 1). 
 
***INSERT TABLE 3 HERE*** 
 
Secondary outcomes 
Differences between intervention and control were not statistically significant for most secondary 
outcomes (see Table 4). Evaluation of clinical markers of recovery (including responder criteria) 
showed no significant differences between groups (see Additional File 2, Table 3). Of the significant 
differences in secondary outcomes, the Patient Enablement Score (mean (SD)) was greater in the 
intervention arm compared with the control arm at six months (3.21 (3.44) vs. 2.29 (2.96)), and also 
at the secondary endpoints of three and 12 months. By contrast PASE scores indicated a fall in 
reporting of physical activity in the intervention arm compared with control (statistically significant 
for the walking domain at three and six months (data not shown)) but this was not clinically 
significant. In those participants receiving both the GP and practice nurse consultations, there was 
an increase in the use of strengthening exercises at three months (data not shown). 
 
***INSERT TABLE 4 HERE*** 
 
Treatment fidelity 
At three months, self-reported consultations with a practice nurse for joint problems had occurred 
in n=70 (28.9%) in the intervention arm compared with n=26 (13.5%) in the control arm. 
 
Adverse events 
No adverse events were reported as a result of the interventions. 
 
DISCUSSION 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
In this cluster-randomised controlled trial there was no evidence of benefit of this intervention, as 
delivered in this pragmatic randomised trial, on the primary clinical outcome (physical functioning) 
at six months after adjustment for predefined potential confounders. However, there were 
significant increases in uptake and use of NICE OA core recommendations in intervention practices 
compared with control over six months. Use of oral NSAIDs was reduced in participants in the 
intervention arm. 
 
We developed three primary care innovations in preparation for this trial: a model OA consultation, 
training to deliver the consultation, and an e-template specifically for use during consultations with 
patients who have OA. The model consultation consisted of an OA guidebook [13,21]; an enhanced 
OA consultation with a GP [15]; and subsequent follow up with a practice nurse in a dedicated OA 
clinic. The training for healthcare professionals was developed to implement delivery of the 
enhanced OA consultation [15]; and the e-template was developed to record quality measures of OA 
care [9,20]. These three innovations provided the tools for implementing NICE Quality Standards for 
OA in general practice [22]. 
 
Clinical guidelines represent a distillation of best evidence about either clinically effective 
interventions and management determined by expert consensus to represent best practice, such as 
information provision. The challenge for clinicians and policy makers is to get such guidelines 
adopted in practice. Our novel intervention has achieved substantial improvements in adoption of 
the guidelines in primary care, and in achieving markers of quality of care for patients with OA. 
Although there was a substantial increase in guideline uptake, there remains a need to achieve 
universally good adoption of recommended management options [9]. 
 
Despite implementation successes in this trial, the expected improvement in clinical outcomes did 
not occur. There are a number of possible explanations. First, it is possible that the lack of effect on 
clinical outcomes reflects a genuine lack of intervention efficacy. Considering the WISE theoretical 
framework as applied to MOSAICS [23], this could relate to the Guidebook, to the responsiveness of 
professionals, or to access to care (the nurse follow-up consultations). As the cost of providing nurse 
clinics was reimbursed, and in some cases staff were directly provided, it seems unlikely that 
insufficient clinic availability was the cause of low uptake but other service pressures or patient or 
clinician beliefs about OA may have affected access to the practice nurse [7]. The GP remained the 
gatekeeper for referral and this could be the main reason why more patients didn’t see the nurse.  
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Most participants had multisite, chronic, joint pain so perhaps it was unrealistic to expect changes in 
a primary outcome with an endpoint of six months for a long-term condition, particularly if patients 
were not already engaged in positive lifestyle behaviours. More specialist clinical services and 
referral for specialist pain-management may have been indicated for some.  
 
Secondly, the clinical outcome measures used may be inappropriate in routine practice for patients 
with multisite OA and multiple morbidities, who may be different to participants in OA clinical trials; 
in particular in the guidelines the evidence base may have been drawn from a narrower clinical 
spectrum of OA. Thirdly, the ‘dose’ of the intervention in practice may have been insufficient to 
improve long-term pain and disability - for example less than a third of participants reported 
consulting the nurse, the focus of the intervention was on supporting self-management, and uptake 
of exercise (known to be clinically effective for OA [24]) may not have been of sufficient intensity to 
achieve additional changes in the SF-12 PCS. Finally, closing the gap between uptake of guideline 
evidence and primary care practice may benefit from multiple strategies, and the best way of 
combining strategies is unknown [25]. Further work is still needed to explore how optimal OA 
management can be provided in primary care. 
 
Of the secondary outcomes, improvement in patient enablement suggests a beneficial effect of the 
intervention on the capacity of patients for self-management – one of the targets of NICE core 
guidance.  
 
Strengths and limitations 
Bias in cluster trials due to differential selection of patients between intervention and control arms is 
a recognised problem [26]. We designed our cluster trial to address these challenges by including a 
pre-recruitment population survey mailed to 30,000 community dwelling adults aged ≥45 years 
registered in primary care in order to identify potentially eligible participants prior to any 
consultation about OA. When any of the individuals subsequently consulted their GP with peripheral 
joint pain, and the GP entered a relevant Read code into the patient’s electronic patient record, the 
patient automatically became eligible for the trial and was posted a baseline post-consultation 
questionnaire to complete. 
 
By removing the process of eligibility checking and recruitment from the GP, we reduced the 
likelihood of selection bias between intervention and control practices. However, in the intervention 
practices in this pragmatic trial, it was clear that GPs had been selective to some extent in their 
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referral of patients for practice nurse consultation, although numbers were too small to ascertain on 
which characteristics patients were selected. Other design strengths included randomisation 
procedures, blinding of the research nurse and use of minimal data in follow-up. Another strength of 
the MOSAICS study was its use of implementation theories [9,15,27]. 
 
Patient and Public Involvement and Engagement was used extensively throughout the MOSAICS 
study, including in co-application for funding, steering group membership, OA guidebook 
development and selection of measures of self-reported quality of OA primary care [9,17,31]. 
 
A weakness of our study was that not all participants recruited in the intervention arm received the 
linked practice nurse consultation, which could have diluted the impact of the intervention. Less 
than a third of participants in the intervention arm saw the practice nurse; further analysis did not 
reveal a clear underlying reason for this. 
 
Since the NICE 2008 guidelines [2], upon which the MOSAICS trial was based, the evidence about the 
role of paracetamol in the pharmacological management of OA has been questioned. Paracetamol 
was promoted as a first-line pharmacological therapy along with topical NSAIDs, and remains a 
recommended option in the NICE 2014 guidelines. A recent systematic review [33] concluded that 
paracetamol adds little to the management of OA and does have risks. 
 
Jordan et al previously described the practice-level evaluation of the intervention in the cluster trial 
using the anonymised medical records [10].  In practice records, supply of written information 
increased in the intervention practices but remained stable in the control practices [10]. We found 
similar results here in the patient-reported QIs. Comparisons can also be made with other studies of 
self-management in primary care. Kennedy et al. [14], implementing the WISE model of self-
management support in primary care, found a lack of clinical benefit. However, our intervention was 
more intense, and we were able to detect change in quality indicators of care - not measured by 
Kennedy et al. [14] - by using patient self-report. These included an increase in non-pharmacological 
approaches and a decline in use of oral NSAIDs. Unlike the study of self-management by Buszewicz 
et al. [34], which improved participants' perceived self-efficacy to manage symptoms, we did not 
find a benefit for pain self-efficacy. However, we did notice an improvement in patient enablement 
scores which could be regarded consistent with Buszewicz’s observation. A German cluster trial of 
self-management support by GPs in adults aged ≥18 years with hip and knee OA noted 
improvements in quality of life associated with the addition of a practice nurse telephone follow-up 
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to support self-management [35]. Further models of implementing OA guidelines have been 
described, compared and contrasted [36]. 
 
In conclusion, although our novel method of delivering and supporting self-management for OA in 
general practice increased the uptake of quality standards of OA care, there was no evidence of 
benefit of this intervention on the primary outcome of physical functioning at six months. 
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Figure 1. Study Flow Chart 
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APPENDIX 1: CLUSTER TRIAL ELIGIBILITY 
Participant Eligibility Criteria 
*Patients 
Inclusion Criteria: 
● Males and Females 
● 45 years and over 
● Registered with a MOSAICS study practice 
● Joint pain in the past year (in the hand, hip, knee, foot) self-reported in the 
Health Survey 
● Consent to further contact from the study team (consent sought as part of 
the Health Survey) 
● Consent to medical record review (consent sought as part of the Health 
Survey) 
 
● Consulting with joint pain in the cluster trial recruitment period  
● Triggered the e-template in EMIS system in the consultation  
● Returned post-consultation baseline Questionnaire  
 
Exclusion Criteria: 
● Excluded via GP screen of practice list 
● Unable to give fully informed consent e.g. learning difficulties or dementia 
● Resident in a care or nursing home 
● History of serious disease e.g. malignancy, terminal illness 
● Unable to consult in the general practice surgery 
● Flagged as excluded from research in that practice 
 
● Declined to take part in the post-consultation baseline Questionnaire 
 
* All patients registered with MOSAICS practices randomised to the intervention arm of the 
study had access to the GP and practice nurse clinics, including those who did not consent 
to be followed up, as these ran as part of normal clinical care within each intervention 
practice. 
 
Key: 
EMIS = Egton Medical Information System; GP = General Practitioners; MOSAICS = 
Management of Osteoarthritis In Consultations Study 
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APPENDIX 2: THE MODEL OA CONSULTATION (MOAC) INTERVENTION AND TRAINING 
A model OA consultation provided a new service for patients in general practice to enhance 
the management of OA based on the NICE OA guidelines [2,3]. The model consultation was 
a linked GP and practice nurse integrated consultation supported by the use of an OA 
Guidebook [13]. The aim of the model OA consultation was to operationalise in general 
practice three aspects of care for OA:  
1. The three core treatments of the NICE OA Guideline (2008)[2]: verbal and written 
information, advice to exercise and increase physical activity, interventions to achieve 
weight loss. 
2. The NICE OA Guideline recommendations for first-line analgesia: paracetamol and 
topical NSAIDs. 
3. Support for self-management of OA based upon the Whole Systems Informing Self-
Management Engagement (WISE) model [14], which centres on the provision of 
knowledge for patients and a style of intervention built on professional responsiveness 
to patients’ needs. 
 
Model OA consultation with the GP 
Patients aged 45 years and over with peripheral joint pain (knee, hip, hand, and foot) had an 
initial consultation with the GP. An OA e-template was triggered as part of the consultation 
and GPs were asked to assess and make a clinical diagnosis of the problem without the 
routine use of x-ray. GPs were then asked to offer an explanation of OA (in suitable 
language and tailored to the patient's level of understanding and individual circumstances) 
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and offer first line analgesia as appropriate (paracetamol; topical NSAIDS). An OA guidebook 
(http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf) 
written by patients and health care professionals for patients was given to the patient. It 
offers support for self-management, promotes the NICE core treatments and provides 
accounts of how people live with OA. The GP was then asked to explain the next steps: for 
the patient to read the OA guidebook and to arrange a follow-up appointment with the 
practice nurse. 
 
Model OA consultation with the practice nurse (nurse-led OA clinic) 
The timing of the first appointment with the practice nurse was planned for a minimum of 
two weeks after the initial GP consultation. This gave patients time to read the guidebook 
and try those self-management strategies they felt were suitable. In the first consultation 
the practice nurse was asked to refer to the guidebook as a resource to answer questions 
and clarify issues, ascertain the advice from the GP consultation, negotiate and agree 
appropriate goals, discuss the need for pain relief and opportunities for healthy eating, 
physical activity and exercise as appropriate.  
The timing of up to three follow-up visits with the nurse was agreed between the patient 
and the practice nurse, but was scheduled to be delivered within three months following 
the GP consultation. The follow-up practice nurse consultations were tailored to the 
patient’s individual needs and could focus on, for example, reviewing the self-management 
plan, demonstrating exercises (Arthritis Research UK Exercises for Arthritis leaflet), giving 
advice as to how this could be maintained longer-term or making any necessary referrals to 
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the broader multidisciplinary team. The practice nurse consultations were supported by a 
specifically tailored Case Report Form (available on request) and a nurse toolkit that 
included advice leaflets to give to patients (content of the toolkit available on request).  
 
Training  
Training and educational packages were developed for GPs and practice nurses by drawing 
on the work of May et al. [28], Grol [29] and Michie et al. [30] Intervention practices 
received practice updates on core NICE recommendations for OA (diagnosis; written 
information [an OA guidebook], exercise and physical activity, healthy eating, pain 
management). GPs received training on the delivery of the initial consultation for a new or 
established patient during four practice-based sessions (2hrs x3, 1hr x1) utilising simulated 
patients in skills training sessions [15]. Practice nurses received four days of training on how 
to support patients to self-manage OA, using a patient-centred approach, the OA 
guidebook, goal setting, pain management (analgesia and exercise) and the core NICE 
recommendations (information and advice, strengthening exercise and aerobic fitness 
training, and weight management), again with the use of simulated patients. 
Members of the wider multidisciplinary team linked to the intervention practices (e.g., 
physiotherapists, occupational therapists, podiatrists, pharmacists) were invited to a 
workshop to inform them of the use of the MOAC intervention in their local general practice 
and its aims. They were given the OA guidebook as reference material, however no change 
to usual care was instigated. 
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Table 1: Summary of General Practice (GP) and individual participant characteristics 
at baseline by study group. 
 
 
GP Practice characteristics* 
 
Intervention n=4 
 
Control n=4 
 
 
Practice size, mean (SD) 
 
 
10240 (9174.8) 
 
6983 (2060.7) 
 
Practice Index of Multiple 
Deprivation rank, 
median (IQR) 
 
9165.0 
(2195.7, 19478.5) 
14633.5 
(4571.5, 28822.0) 
Number of General 
Practitioners, 
mean (SD) 
 
 
6.0 (6.1) 
 
5.5 (2.9) 
Age (years) of GP, mean (SD) 
 
42.2 (23.7) 42.8 (23.5) 
   
Participants characteristics Intervention n=288 Control n=237 
 
   
Gender, n (%) 
  
Female 167 (58.0) 146 (61.6) 
Male 
 
121 (42.0) 91 (38.4) 
Age (years) mean (SD) 
 
66.9 (10.6) 67.7 (10.3) 
BMI (kgm-2), mean (SD) 28.1 (5.1) 28.5 (4.8) 
 
  
Marital status, n (%) 
  
Married 186 (65.0) 168 (71.0) 
Separated 2 (0.7) 4 (1.7) 
Divorced 29 (10.1) 13 (15.6) 
Widowed 44 (15.4) 37 (15.6) 
Cohabiting 10 (3.5) 9 (3.8) 
Single 
 
15 (5.2) 6 (2.5) 
Employment status, n (%) 
  
Employed 77 (27.2) 59 (25.2) 
Not working/Retired 
 
206 (72.8) 175 (74.8) 
Deprivation Index, 
  
Median (IQR) 
 
21868 (15144, 28649) 20182 (15989, 24635) 
No. of pain sites, n (%) 
  
1 55 (19.1) 45 (19.0) 
2 or more 
 
233 (80.9) 192 (81.0) 
 
* Age and gender structure of the registered population at the practices was similar to that of North Staffordshire and of 
England and Wales.  Practices had a range of numbers of patients, a range of areas - semi rural to urban (small town / 
larger city), and a range of deprivation.
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Table 2: Effectiveness of the Model Osteoarthritis Consultation on the primary outcome measure (SF-12 PCS) compared to usual primary 
care for osteoarthritis 
 Intervention Control    
SF-12 PCS Valid n Mean SD 
Valid 
n Mean SD 
*Mean 
difference  
(95% CI) 
**Effect size 
(95% CI) 
 
p-value 
Post-consultation 280 36.49 11.48 231 36.48 11.00 - - - 
3 months 250 38.03 12.32 204 38.12 11.58 
-0.29 
(-1.86, 1.29) 
-0.03 
(-0.17, 0.11) 
 
0.722 
6 months 229 38.99 12.12 180 38.89 12.00 
-0.37 
(-2.32, 1.57) 
-0.03 
(-0.21, 0.14) 
 
0.706 
12 months 200 38.79 12.58 166 39.22 11.84 
-0.90 
(-3.75, 1.96) 
-0.08 
(-0.33, 0.17) 
 
0.539 
*Calculated as mean difference for Intervention group - control group by linear mixed modelling adjusted for age, gender, practice size and 
baseline SF-12 PCS (clustering by general practice accounted for in the mixed model). 
** Mean difference relative to pooled ‘baseline’ (post-consultation) SD. 
ICC: 0.006 (unadjusted); <0.001 (adjusted for baseline score). 
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Table 3: Self-report Quality Indicators of osteoarthritis care and treatment used within the first 6 months of consultation. 
Self-reported OA Quality Indicators Intervention Control OR (95% CI) Absolute % difference
∆
 
(95% CI) 
P-value 
Treatment offered      
‡Educa7on, advice and access to informa7on 95.0% 91.5% 2.95 (0.68, 12.8) 5.4% (-3.5%, 7.7%) 0.148 
Support on how to help self with joint problem 66.9% 60.1% 1.91 (0.95, 3.81) 14.1% (-1.1%, 25.1%) 0.068 
Information/advice about exercises, muscle strengthening 
or physical activities  81.5% 63.3% 
 
3.01 (1.43, 6.32) 
 
20.5% (7.9%, 28.3%) 
 
0.004 
Referral to strengthening or physical activities  54.4% 46.9% 1.45 (0.85, 2.55) 9.2% (-3.9%, 22.3%) 0.126 
#Advice to lose weight 46.3% 43.0% 1.33 (0.79, 2.24) 7.0% (-5.7%, 19.8%) 0.288 
#Referral to services for losing weight 16.4% 12.9% 2.92 (0.85, 9.98) 17.3% (-1.7%, 46.7%) 0.087 
Paracetamol recommended for pain 79.7% 70.3% 1.80 (1.03, 4.25) 10.7% (0.6%, 20.7%) 0.037 
Stronger painkiller 69.4% 68.8% 1.18 (0.71, 1.95) 3.4% (-7.8%, 12.3%) 0.529 
Information about drugs effect provided 68.2% 72.6% 0.65 (0.39, 1.09) -9.2% (-21.6%, 1.6%) 0.101 
Corticosteroid joint injection 35.2% 35.8% 1.12 (0.64, 1.84) 2.6% (-9.6%, 14.8%) 0.677 
Surgery evaluation 32.3% 37.0% 0.82 (0.42, 1.62) -4.4% (-17.3%, 11.8%) 0.574 
Need for walking aid assessed 28.9% 28.9% 1.05 (0.60, 1.65) 1.0% (-9.3%, 11.3%) 0.853 
Need for appliances/aids to daily living 14.4% 18.2% 0.91 (0.45, 1.82) -1.4% (-9.1%, 10.6%) 0.780 
Treatment used      
‡Educa7on, advice and access to informa7on 62.0% 47.6% 2.67 (1.62, 4.40) 23.2% (11.9%, 32.4%) <0.001 
Muscle strengthening exercises 60.5% 44.3% 1.91 (1.20, 3.20) 16.0% (4.4%, 27.5%) 0.007 
General fitness exercises 38.0% 35.4% 0.80 (0.45, 1.29) -4.8% (-15.6%, 6.0%) 0.384 
Physiotherapy 40.1% 38.6% 0.65 (0.38, 1.13) -9.5% (-19.4%, 2.9%) 0.126 
#Dieting to lose weight 48.4% 50.9% 0.87 (0.52, 1.44) -3.6% (-16.0%, 8.9%) 0.577 
Paracetamol  86.5% 84.8% 1.24 (0.63, 2.44) 2.6% (-7.0%, 8.4%) 0.535 
Anti-inflammatory creams/gels e.g. topical NSAIDs 81.6% 79.8% 1.21 (0.67, 2.21) 2.9% (-7.3%, 9.9%) 0.527 
Capsaicin cream 21.8% 19.4% 1.55 (0.87, 2.77) 7.7% (-2.2%, 20.6%) 0.141 
Anti-inflammatory tablets, e.g. oral NSAIDs 59.9% 70.6% 0.51 (0.31, 0.85) -15.6% (-28.3%, -3.5%) 0.010 
Stronger painkillers, e.g. Opioids 62.9% 62.6% 1.12 (0.70, 1.80) 2.7% (-8.6%, 12.5%) 0.626 
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Community pharmacy 25.8% 16.5% 1.84 (1.02, 3.34) 10.2% (0.3%, 23.3%) 0.043 
Walking aids 41.9% 50.4% 0.57 (0.34, 0.94) -13.9% (-24.6%, -1.6%) 0.027 
Shock-absorbing shoes or insoles 34.8% 31.8% 1.34 (0.81, 2.21) 6.6% (-4.5%, 18.9%) 0.259 
Appliances and support and braces 33.0% 36.9% 0.78 (0.44, 1.25) -5.5% (-16.3%, 5.4%) 0.321 
Assistive devices 25.1% 25.2% 1.35 (0.81, 2.07) 6.1% (-3.7%, 15.9%) 0.222 
Transcutaneous electric nerve stimulation (TENS) 16.2% 16.4% 0.98 (0.52, 1.82) -0.3% (-7.1%, 9.9%) 0.944 
Warmth, heat or cold application 61.2% 58.4% 1.10 (0.69, 1.75) 2.3% (-9.1%, 12.7%) 0.688 
Results were derived through multiple imputation of missing data using chained equations with mixed models for estimating coefficients 
(hence, denominator population n=525; except for # which included 390 participants classified as clinically overweight or obese (classified as 
having a BMI≥25kgm-2)).  
∆ Absolute percent differences were calculated by applying odds ratios derived by logistic mixed regression adjusted for age, sex and practice 
size to percent figures for the reference (control group) (clustering by GP Practice accounted for in the mixed model). % difference relates to % 
in intervention group - % in control group.  
‡ Comprises wriGen or verbal informa7on about joint problem, informa7on about treatments and advice on self-management of joint 
problem.
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Table 4: Effectiveness of the Model Osteoarthritis Consultation compared to usual primary care for osteoarthritis: Evaluation of secondary 
outcomes 
 
Outcome 
Intervention Control    
Valid 
n Mean SD 
Valid 
n Mean SD 
*Mean Difference 
(95% CI) 
**Effect size (95% CI) 
p-value 
Pain intensity scores  
Hip  
Post-consultation 274 3.52 3.47 234 3.38 3.34 - - - 
3 months 241 2.98 3.16 190 3.04 3.28 -0.19 (-0.63, 0.26) -0.06 (-0.18, 0.08) 0.415 
6 months 212 2.59 3.09 172 2.78 3.17 -0.24 (-0.78, 0.30) -0.07 (-0.23, 0.09) 0.382 
12 months 187 2.79 3.13 155 2.71 2.97 -0.15 (-0.90, 0.59) -0.04 (-0.26, 0.17) 0.687 
Knee    
Post-consultation 278 5.67 3.09 230 5.63 3.28 - - - 
3 months 247 4.64 3.11 195 4.69 3.14 -0.49 (-0.94, -0.05) -0.15 (-0.30, -0.02)  0.031 
6 months 215 4.27 3.01 173 4.68 3.17 -0.20 (-0.74, 0.34) -0.06 (-0.23, 0.11) 0.468 
12 months 190 4.25 3.32 159 3.89 3.08 0.04 (-0.71, 0.80) 0.01 (-0.22, 0.25) 0.909 
Hand   
Post-consultation 273 2.94 3.11 230 2.99 3.22 - - - 
3 months 245 2.62 2.83 194 2.61 2.86 -0.15 (-0.56, 0.25) -0.05 (-0.18, 0.08) 0.458 
6 months 213 2.57 2.78 170 2.89 3.02 -0.09 (-0.57, 0.38) -0.03 (-0.18, 0.12) 0.697 
12 months 189 2.80 2.86 157 2.91 3.02 -0.40 (-1.04, 0.24) 0.13 (-0.33, 0.08) 0.218 
Foot   
Post-consultation 275 2.79 3.12 231 2.97 3.34 - - - 
3 months 245 2.36 2.85 192 2.44 3.04 0.03 (-0.41, 0.47) 0.01 (-0.13, 0.15) 0.904 
6 months 209 2.43 2.92 170 2.46 3.08 0.30 (-0.23, 0.83) 0.09 (-0.07, 0.26) 0.272 
12 months 189 2.48 3.05 157 2.45 3.14 0.27 (-0.45, 0.99) 0.08 (-0.14, 0.31) 0.461 
WOMAC physical function  
Post-consultation 283 12.28 7.61 233 12.09 6.87 - - - 
3 months 250 10.56 7.73 196 10.32 6.84 -0.36 (-1.24, 0.52) -0.05 (-0.17, 0.07) 0.417 
6 months 219 9.67 7.21 175 10.46 7.10 -0.53 (-1.68, 0.61) -0.07 (-0.23, 0.08) 0.362 
12 months 191 10.24 7.53 161 9.28 6.65 0.13 (-1.64, 1.90) 0.02 (-0.23, 0.26) 0.884 
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Outcome 
Intervention Control    
Valid 
n Mean SD 
Valid 
n Mean SD 
*Mean Difference 
(95% CI) 
**Effect size (95% CI) 
p-value 
AIMS 2 hand & finger function  
Post-consultation 279 1.62 2.04 233 1.82 2.53 - - - 
3 months 243 1.64 2.09 197 1.56 2.05 0.16 (-0.16, 0.48) 0.07 (-0.07, 0.21) 0.331 
6 months 220 1.55 2.10 175 1.73 2.26 0.02 (-0.35, 0.39) 0.01 (-0.15, 0.17) 0.932 
12 months 192 1.51 2.11 161 1.70 2.21 -0.17 (-0.67, 0.33) -0.07 (-0.29, 0.14) 0.505 
IPAQ          
Post-consultation 
3 months 
6 months 
12 months 
200 
182 
181 
167 
2745 
2378 
2200 
2356 
3285 
2912 
2967 
2414 
171 
157 
144 
142 
3125 
3306 
2519 
3041 
3830 
4073 
 2787 
3460 
- 
- 693 (-1447, 60) 
-629 (-1397, 139) 
-595 (-1396, 207) 
- 
-0.20 (-0.41, 0.02) 
-0.18 (-0.41,0.02) 
-0.17 (-0.39,0.06) 
- 
0.071 
0.108 
0.146 
Physical Activity for the 
Elderly (PASE) 
 
Post-consultation 
3 months 
6 months 
12 months 
237 
203 
190 
157 
138.7 
123.6 
123.0 
134.2 
75.9 
72.0 
68.7 
69.6 
195 
176 
143 
142 
147.5 
149.1 
136.2 
148.2 
85.3 
90.6 
73.2 
77.9 
- 
-22.1 (-35.7, -8.5) 
-18.3 (-34.0, -2.6) 
-17.0 (-38.2, 4.1) 
- 
-0.28 (-0.44, 0.11) 
-0.23 (-0.42, -0.03) 
-0.21 (-0.48, 0.05) 
- 
0.001 
0.022 
0.127 
PHQ8  
Post-consultation 286 5.02 5.24 235 4.45 4.65 - - - 
3 months 248 4.36 4.50 199 3.85 4.64 0.38 (-0.29, 1.04) 0.08 (-0.06, 0.21) 0.265 
6 months 223 4.07 4.87 174 4.29 4.74 0.02 (-0.74, 0.78) 0.00 (-0.15, 0.16) 0.965 
12 months 194 4.06 4.74 162 3.96 4.81 -0.16 (-1.18, 0.86) -0.03 (-0.24, 0.17) 0.759 
GAD7  
Post-consultation 273 3.70 4.89 231 3.22 4.33 - - - 
3 months 242 3.16 4.32 195 2.90 4.60 -0.07 (-0.72, 0.58) -0.02 (-0.15, 0.12) 0.825 
6 months 212 2.72 4.05 172 2.73 4.28 0.60 (-0.15, 1.35) 0.13 (-0.03, 0.29) 0.115 
12 months 187 2.90 4.31 159 2.75 3.84 -0.45 (-1.47, 0.57) -0.10 (-0.32, 0.12) 0.388 
SF-12 MCS  
Post-consultation 280 50.24 11.34 231 51.14 10.91 - - - 
3 months 250 51.04 10.74 204 50.91 11.13 0.09 (-1.64, 1.82) 0.01 (-0.15, 0.16) 0.917 
6 months 229 50.90 10.81 180 50.79 10.66 -0.18 (-2.11, 1.75) -0.02 (-0.19, 0.16) 0.853 
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Outcome 
Intervention Control    
Valid 
n Mean SD 
Valid 
n Mean SD 
*Mean Difference 
(95% CI) 
**Effect size (95% CI) 
p-value 
12 months 200 51.49 10.74 166 51.34 10.11 0.08 (-2.39, 2.55) 0.01 (-0.22, 0.23) 0.947 
Arthritis Self-Efficacy Pain 
Subscale 
 
Post-consultation 282 5.40 1.99 232 5.39 2.11 - - - 
3 months 246 5.82 2.18 190 5.82 2.13 -0.13 (-0.50, 0.25) -0.06 (-0.25, 0.12) 0.516 
6 months 218 5.86 2.08 173 5.82 2.31 0.00 (-0.44, 0.43) 0.00 (-0.22, 0.21) 0.984 
12 months 197 5.83 2.24 157 6.04 2.17 -0.15 (-0.74, 0.44) -0.07 (-0.36, 0.22) 0.615 
Patient Enablement  
Post-consultation - - - - - - - - - 
3 months 253 2.82 3.16 202 2.61 3.25 0.86 (0.10, 1.63) 0.27 (0.03, 0.51) 0.027 
6 months 224 3.21 3.44 178 2.29 2.96 1.34 (0.59, 2.10) 0.42 (0.18, 0.65) <0.001 
12 months 198 2.80 3.18 162 2.59 3.19 0.88 (0.05, 1.71) 0.27 (0.02, 0.53) 0.039 
*Calculated as mean difference for Intervention - Control score by linear mixed modelling adjusted for age, gender, practice size and corresponding baseline 
measures (clustering by GP Practice accounted for in the mixed model). 
** Mean difference relative to pooled ‘baseline’ (post-consultation) SD except for patient enablement for which the relative SD was that of the SD at follow 
up (since no baseline patient enablement was collected).  
ICC (unadjusted): Hip pain <0.001; Knee pain <0.001; Hand pain 0.003; Foot pain 0.016; WOMAC-pf <0.001; AIMS <0.001; IPAQ <0.001; PASE <0.001; PHQ 
<0.001; GAD <0.001; SF-MCS 0.001; self-efficacy 0.001; patient enablement 0.010. 
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610 excluded after mailing 
· Refusal to participate (n=212)
· Incomplete/blank/missing questionnaire (n=111)
· Deaths and departures (n=65)
· Other reasons –mostly due to incorrect person completing the 
questionnaire (n=222)
Non-responders
(n=12,750) 
Responders to the mailed survey
(n=15,083) 
Responders with no joint pain 
(n=3,155) 
Responders with joint pain 
 (n=11,928) 
No consent to MRR & further contact (n=638) 
Responders with consent to MRR & further
contact (n=11,290) 
Did not consult in the trial period
(n= 2,180)
Consent to MRR & further contact 
and consulted with pain in any joint in the trial period 
(n=9,110) 
Randomised: 8 practices
List size: mean (range) = 8611.9 (3978 to 23868)
Randomised to Control Group: 4 practices
 (List size: mean (range) = 6,983.3 (3,978 to 8,461)
Randomised to Intervention Group: 4 practices
List size: mean (range) = 10,240.5 (4,077 to 23,868)
Potentially eligible: 4,408 patients Potentially eligible: 4,702 patients
Consulted in recruitment period and 
eligible to be mailed questionnaire: 287
Consulted in recruitment period and 
eligible to be mailed questionnaire: 364
Responders recruited to the cluster 
trial: 237
Responders recruited to the cluster 
trial: 288
Non-consent/ Exclusions: 50
· Did not wish to take part (15); 
· Non-responders (32);
· Withdrawn (1); 
· Wrong address (2)
Non-consent/ Exclusions: 76
· Did not wish to take part (3)
· Non-responders (70)
· Refused (1)
· Poor health (1)
· Moving address (1)
Follow-up
l  3 months: 210 (88.6%) total 
responders
- 202 main questionnaire returns
- 8 MDC returns
l  6 months: 185 (78.1%) total 
responders
- 178 main questionnaire returns
- 7 MDC returns
l  12 months: 172 (72.6%) total 
responders
- 162 main questionnaire returns
- 10 MDC returns
Withdrawals between baseline and 12 
months: 21
· Did not wish to take further part in 
the study (17, 7.2%)
· Due to ill health (1, 0.4%)
· Non-responders (2, 0.8%)
· No longer at the address (1, 0.4%)
Follow-up
l  3 months: 260 (90.3%) total 
responders
- 253 main questionnaire returns
- 7 MDC returns
l  6 months: 239 (83.0%) total 
responders
- 224 main questionnaire returns
- 15 MDC returns
l  12 months: 212 (73.6%) total 
responders
- 199 main questionnaire returns
- 13 MDC returns
Withdrawals between baseline and 12 
months: 27
· Did not wish to take further part in 
the study again (20, 7.0%)
· Withdrawal due to ill health (2, 
0.7%)
· Non responders (3, 1.0%)
· No longer at the address (2, 0.7%)
Analysed (primary outcome – SF12-PCS)
4 practices
237 patients according to ITT 
  173 analysed according to CACE 
Analysed (primary outcome – SF12-PCS)
4 practices
237 patients according to ITT 
  173 analysed according to CACE 
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215 analysed according to CACE 
